Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8715451-mallinckrodt-and-massachusetts-general-hospital-study-inomax-covid-19-effectiveness/
The study is titled "Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19."
"Data suggest that inhaled nitric oxide may have an important role in helping patients with acute respiratory distress syndrome (ARDS) to achieve normal oxygen levels in the blood," said
The primary focus of the study is to assess the potential efficacy of inhaled nitric oxide to rapidly reverse hypoxemia (abnormally low oxygen levels in the blood) in patients with severe COVID-19 lung complications . Specifically, it will determine the difference in oxygenation in patients after 48 hours of treatment. Secondary objectives include evaluating the time it takes for patients who are breathing air to reach normoxia (normal oxygen levels in the blood) for at least 24 hours; the proportion of patients who achieve normoxia during the first 28 days after enrollment; and the patient survival rate at 28 days and 90 days, among other objectives.
"Patients around the world are in need of science-based therapies that can effectively fight this life-threatening disease, and Mallinckrodt is committed to assisting health providers and government agencies to research and identify possible solutions to help relieve this global crisis," said
The trial initiation follows Mallinckrodt's earlier announcement of a research project in
More than 170 hospitals and health systems in the
Mallinckrodt encourages hospitals to contact the company's Customer Care center 1-877-566-9466 with any questions related to INOmax. The Customer Care team is available 24 hours a day, seven days a week to respond to inquiries.
INOmax has been on the market in the
COVID-19 is a respiratory illness that can spread from person to person. It is caused by a novel coronavirus. Patients with COVID-19 may have mild to severe respiratory illness that can include symptoms such as cough, fever and shortness of breath.2 In severe cases, COVID-19 can cause ARDS – a disorder in which fluid leaks into the lungs, making breathing difficult or impossible – and can lead to multi-organ failure and sometimes death.2,3
INOmax® (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
IMPORTANT SAFETY INFORMATION
Please see Full Prescribing Information.
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the
CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements concerning inhaled nitric oxide ("iNO") and the Company's iNO product, including statements with regard to potential regulatory developments, the potential impact of iNO on patients and anticipated benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the
For Media Inquiries
Senior Vice President
M: +1 813 545 2399
Vice President, Investor Relations and IRO
Senior Vice President, Government Affairs
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. ©2020 Mallinckrodt. US-2000808 04/20
1 Mallinckrodt, Data on File
3 Matthay MA, Aldrich JM, Gotts, JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med. 2020. Published Online March 20, 2020. https://doi.org/10.1016/S2213-2600(20)30127-2.
View original content:http://www.prnewswire.com/news-releases/mallinckrodt-supports-investigator-initiated-study-at-massachusetts-general-hospital-to-assess-effectiveness-of-inhaled-nitric-oxide-in-patients-with-severe-acute-respiratory-distress-syndrome-due-to-covid-19-301050079.html
SOURCE Mallinckrodt Pharmaceuticals